Making Old Bones New! Where Do We Stand?

The word “osteoporosis” comes from Greek – porous bones. More than 40 million Americans either already have osteoporosis or are at high risk for this “silent disease” due to low bone mass. Complications are frightening: About one in two women and up to one in four men over the age of 50 will break a bone due to osteoporosis.

Current treatment and prevention options for osteoporosis involve diet, exercise and medication. What’s on the horizon?

Simon Melov, PhD is an Associate Professor at the Buck Institute and directs our Genomics Core, which provides genome-wide analysis and consultation for many of the labs at the Institute. The Melov lab studies the cell biology of osteoporosis, using single cells isolated from the bone itself. In collaboration with other faculty, Dr. Melov is also focused on drugs that can extend the healthspan of animals, and may have translational potential in human beings.

Clifford Rosen, MD is the Director of Clinical and Translational Research at Maine Medical Center’s Research Institute. A nationally-recognized expert on osteoporosis, he is also an Adjunct Faculty member at the Buck and is collaborating on projects with the Melov, Lithgow and Campisi labs. He has overseen numerous clinical trials and is a member of the FDA Advisory Panel on Endocrinologic and Metabolic Drugs. His research is focused on developing new drugs for osteoporosis.

Registration is required
Complimentary admission
Suggested donation: $10

For more information and to register, contact us at:
seminars@buckinstitute.org
415.209.2045